请输入您要查询的百科知识：

　

词条 Tumor-associated macrophage
释义

  1. Function

     Angiogenesis  Immune suppression 

  2. Subtypes

  3. Clinical significance

  4. As a drug target

  5. See also

  6. References

Tumor-associated macrophages (TAMs) are a class of immune cells present in high numbers in the microenvironment of solid tumors. They are heavily involved in cancer-related inflammation. Macrophages are known to originate from bone marrow-derived blood monocytes (monocyte-derived macrophages) or yolk sac progenitors (tissue-resident macrophages), but the exact origin of TAMs in human tumors remains to be elucidated.[1] The composition of monocyte-derived macrophages and tissue-resident macrophages in the tumor microenvironment depends on the tumor type, stage, size, and location, thus it has been proposed that TAM identity and heterogeneity is the outcome of interactions between tumor-derived, tissue-specific, and developmental signals.[2]

Function

Although there is some debate, most evidence suggests that TAMs have a tumor-promoting phenotype. TAMs affect most aspects of tumor cell biology and drive pathological phenomena including tumor cell proliferation, tumor angiogenesis, invasion and metastasis, immunosuppression, and drug resistance.[3][4]

Angiogenesis

Tumor angiogenesis is the process by which a tumor forms new blood vessels in order to maintain a supply of nutrients and oxygen and to grow beyond a few millimeters in size. The formation of vasculature also facilitates the escape of malignant cells into blood circulation and the onset of metastasis. One of the primary tumor-promoting mechanisms of TAMs is the secretion of potent pro-angiogenic factors. The most highly expressed and well-characterized angiogenic factor produced by TAMs is vascular endothelial growth factor A (VEGF-A).[5] TAMs accumulate in hypoxic regions of the tumor, which induces the expression of hypoxia-inducible factors (HIF-1) that regulate VEGF expression. In addition to producing VEGF-A, TAMs have been shown to modulate VEGF-A concentration through matrix metalloproteinase (MMP)-9 activity[6] and by producing WNT7B that induces endothelial cells to produce VEGF-A.[7]

In addition to VEGF-A, TAMs secrete the pro-angiogenic factors tumor necrosis factor α (TNFα), basic fibroblast growth factor, urokinase-type plasminogen activator, adrenomedullin, and semaphorin 4D.[5] Moreover, cytokines produced by TAMs induce tumor cells to produce pro-angiogenic factors, thereby working cooperatively to turn on the angiogenic switch.

A class of TAMs expressing Tie2 have been shown to induce tumor angiogenesis.[8] Tie2+ TAMs associate with blood vessels through angiopoietin-2 produced by endothelial cells and activate angiogenesis through paracrine signaling. When angiopoietin-2 is bound, these TAMs upregulate expression of more angiogenic factors, such as thymidine phosphorylase and cathepsin B. Angiopoietin-2 also causes Tie2+ TAMs to express T-cell regulating factors interleukin (IL)-10 and chemokine (C-C motif) ligand (CCL) 17; these factors limit T-cell proliferation and upregulate expansion of regulatory T cells, allowing tumor cells to evade immune responses.[9] Moreover, tumor-produced colony stimulating factor-1 (CSF1), which regulates macrophage lineage, increases expression of Tie2 on TAMs, suggesting that CSF1 and Tie2+ TAMs may play a role in the angiogenic switch.[10]

Tumor lymphangiogenesis is closely related to tumor angiogenesis, and there is substantial evidence that factors produced by TAMs, especially those of the VEGF family and their receptor tyrosine kinases, are responsible for this link.[11][12]

Immune suppression

One of the major functions of TAMs is suppressing the T-cell mediated anti-tumor immune response. Gene expression analysis of mouse models of breast cancer and fibrosarcoma shows that TAMs have immunosuppressive transcriptional profiles and express factors including IL-10 and transforming growth factor β (TGFβ).[13][14] In humans, TAMs have been shown to directly suppress T cell function through surface presentation of programmed death-ligand 1 (PD-L1) in hepatocellular carcinoma[15] and B7-homologs in ovarian carcinoma,[16] which activate programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4), respectively, on T cells. Inhibitory signals to PD-1 and CTLA-4 are immune checkpoints, and binding of these inhibitory receptors by their ligands prevents T cell receptor signaling, inhibits T cells cytotoxic function, and promotes T cell apoptosis.[2][17] HIF-1α also induces TAMs to suppress T cell function through arginase-1, but the mechanism by which this occurs is not yet fully understood.[18] Recently, Siglec-15 has also been identified as an immune suppressive molecule that is solely expressed on TAMs, and could be a potential therapeutic target for cancer immunotherapy. [19]

Subtypes

TAMs have historically been described as falling into two categories: M1 and M2. M1 refers to macrophages that undergo “classical” activation by interferon-γ (IFNγ) with either lipopolysaccharide (LPS) or TNF, whereas M2 refers to macrophages that undergo “alternative” activation by IL-4.[20] M1 macrophages are seen to have a pro-inflammatory and cytotoxic (anti-tumoral) function; M2 macrophages are anti-inflammatory (pro-tumoral) and promote wound healing. However, use of the M1/M2 polarization paradigm has led to confusing terminology since M1/M2 are used to describe mature macrophages, but the activation process is complex and involves many related cells in the macrophage family. Moreover, with recent evidence that macrophage populations are tissue- and tumor-specific,[2] it has been proposed that classifying macrophages, including TAMs, as being in one of two distinct stable subsets is insufficient.[20] Rather, TAMs should be viewed as existing on a spectrum. More comprehensive classification systems that account for the dynamic nature of macrophages have been proposed,[2] but have not been adopted by the immunological research community.

Clinical significance

In many tumor types TAM infiltration level has been shown to be of significant prognostic value. TAMs have been linked to poor prognosis in breast cancer, ovarian cancer, types of glioma and lymphoma; better prognosis in colon and stomach cancers and both poor and better prognoses in lung and prostate cancers.[21]

Clinically, in 128 patients with breast cancer it was found that patients with more M2 tumor-associated macrophages had higher-grade tumors, greater microvessel density, and worse overall survival. Patients with more M1 tumor-associated macrophages displayed the opposite effect.[22][23]

As a drug target

CSF1R inhibitors have been developed as a potential route to reduce the presence of TAMs in the tumor microenvironment.[24] As of 2017, CSF1R inhibitors that are currently in early stage clinical trials include Pexidartinib, PLX7486, ARRY-382, JNJ-40346527, BLZ945, Emactuzumab, AMG820, IMC-CS4, MCS110, and Cabiralizumab.[25][26][27][28] CSF1R inhibitors such as PLX3397 have also been shown to alter the distribution of TAMs throughout the tumor and promote enrichment of the classically activated M1-like phenotype.[29][30]

Other approaches to enhance tumor response to chemotherapies that have been tested in preclinical models include blocking macrophage recruitment to the tumor site, re-polarizing TAMs, and promoting TAM activation.[31] Remaining challenges in targeting TAMs include determining whether to target depletion or repolarization in combination therapies, and for which tumor types and at what tumor stage TAM-targeted therapy is effective.[31] Re-polarization of TAMs from a M2 to M1 phenotype by drug treatments has shown the ability to control tumor growth,[32] including in combination with checkpoint inhibitor therapy.[30]

See also

  • Tumor microenvironment

References

1. ^{{cite journal|last1=Komohara|first1=Yoshihiro|last2=Fujiwara|first2=Yukio|last3=Ohnishi|first3=Koji|last4=Takeya|first4=Motohiro|title=Tumor-associated macrophages: Potential therapeutic targets for anti-cancer therapy|journal=Advanced Drug Delivery Reviews|date=April 2016|volume=99|issue=Pt B|pages=180–185|doi=10.1016/j.addr.2015.11.009|pmid=26621196}}
2. ^1 2 3 {{cite journal|last1=Ostuni|first1=Renato|last2=Kratochvill|first2=Franz|last3=Murray|first3=Peter J.|last4=Natoli|first4=Gioacchino|title=Macrophages and cancer: from mechanisms to therapeutic implications|journal=Trends in Immunology|date=April 2015|volume=36|issue=4|pages=229–239|doi=10.1016/j.it.2015.02.004|pmid=25770924}}
3. ^{{cite journal|last1=Qian|first1=Bin-Zhi|last2=Pollard|first2=Jeffrey W.|title=Macrophage Diversity Enhances Tumor Progression and Metastasis|journal=Cell|date=April 2010|volume=141|issue=1|pages=39–51|doi=10.1016/j.cell.2010.03.014|pmid=20371344|pmc=4994190}}
4. ^{{cite journal|last1=Mantovani|first1=Alberto|last2=Marchesi|first2=Federica|last3=Malesci|first3=Alberto|last4=Laghi|first4=Luigi|last5=Allavena|first5=Paola|title=Tumour-associated macrophages as treatment targets in oncology|journal=Nature Reviews Clinical Oncology|date=24 January 2017|volume=14|issue=7|pages=399–416|doi=10.1038/nrclinonc.2016.217|pmid=28117416|pmc=5480600}}
5. ^1 {{cite journal|last1=Riabov|first1=Vladimir|last2=Gudima|first2=Alexandru|last3=Wang|first3=Nan|last4=Mickley|first4=Amanda|last5=Orekhov|first5=Alexander|last6=Kzhyshkowska|first6=Julia|title=Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis|journal=Frontiers in Physiology|date=5 March 2014|volume=5|pages=75|doi=10.3389/fphys.2014.00075|pmid=24634660|pmc=3942647}}
6. ^{{cite journal|last1=Bergers|first1=Gabriele|last2=Brekken|first2=Rolf|last3=McMahon|first3=Gerald|last4=Vu|first4=Thiennu H.|last5=Itoh|first5=Takeshi|last6=Tamaki|first6=Kazuhiko|last7=Tanzawa|first7=Kazuhiko|last8=Thorpe|first8=Philip|last9=Itohara|first9=Shigeyoshi|last10=Werb|first10=Zena|last11=Hanahan|first11=Douglas|title=Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis|journal=Nature Cell Biology|date=1 October 2000|volume=2|issue=10|pages=737–744|doi=10.1038/35036374|pmid=11025665|pmc=2852586}}
7. ^{{cite journal|last1=Yeo|first1=E.-J.|last2=Cassetta|first2=L.|last3=Qian|first3=B.-Z.|last4=Lewkowich|first4=I.|last5=Li|first5=J.-f.|last6=Stefater|first6=J. A.|last7=Smith|first7=A. N.|last8=Wiechmann|first8=L. S.|last9=Wang|first9=Y.|last10=Pollard|first10=J. W.|last11=Lang|first11=R. A.|title=Myeloid WNT7b Mediates the Angiogenic Switch and Metastasis in Breast Cancer|journal=Cancer Research|date=17 March 2014|volume=74|issue=11|pages=2962–2973|doi=10.1158/0008-5472.CAN-13-2421|pmid=24638982|pmc=4137408}}
8. ^{{cite journal|last1=De Palma|first1=Michele|last2=Venneri|first2=Mary Anna|last3=Galli|first3=Rossella|last4=Sergi|first4=Lucia Sergi|last5=Politi|first5=Letterio S.|last6=Sampaolesi|first6=Maurilio|last7=Naldini|first7=Luigi|title=Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors|journal=Cancer Cell|date=September 2005|volume=8|issue=3|pages=211–226|doi=10.1016/j.ccr.2005.08.002|pmid=16169466}}
9. ^{{cite journal|last1=Coffelt|first1=Seth B.|last2=Chen|first2=Yung-Yi|last3=Muthana|first3=Munitta|last4=Welford|first4=Abigail F.|last5=Tal|first5=Andrea O.|last6=Scholz|first6=Alexander|last7=Plate|first7=Karl H.|last8=Reiss|first8=Yvonne|last9=Murdoch|first9=Craig|last10=De Palma|first10=Michele|last11=Lewis|first11=Claire E.|title=Angiopoietin 2 Stimulates TIE2-Expressing Monocytes To Suppress T Cell Activation and To Promote Regulatory T Cell Expansion|journal=The Journal of Immunology|date=1 April 2011|volume=186|issue=7|pages=4183–4190|doi=10.4049/jimmunol.1002802|pmid=21368233}}
10. ^{{cite journal|last1=Forget|first1=Mary A.|last2=Voorhees|first2=Jeffrey L.|last3=Cole|first3=Sara L.|last4=Dakhlallah|first4=Duaa|last5=Patterson|first5=Ivory L.|last6=Gross|first6=Amy C.|last7=Moldovan|first7=Leni|last8=Mo|first8=Xiaokui|last9=Evans|first9=Randall|last10=Marsh|first10=Clay B.|last11=Eubank|first11=Tim D.|last12=Valledor|first12=Annabel|title=Macrophage Colony-Stimulating Factor Augments Tie2-Expressing Monocyte Differentiation, Angiogenic Function, and Recruitment in a Mouse Model of Breast Cancer|journal=PLoS ONE|date=3 June 2014|volume=9|issue=6|pages=e98623|doi=10.1371/journal.pone.0098623|pmid=24892425|pmc=4043882}}
11. ^{{cite journal|last1=Gomes|first1=Fausto Gueths|last2=Nedel|first2=Fernanda|last3=Alves|first3=Alessandro Menna|last4=Nör|first4=Jacques Eduardo|last5=Tarquinio|first5=Sandra Beatriz Chaves|title=Tumor angiogenesis and lymphangiogenesis: Tumor/endothelial crosstalk and cellular/microenvironmental signaling mechanisms|journal=Life Sciences|date=February 2013|volume=92|issue=2|pages=101–107|doi=10.1016/j.lfs.2012.10.008|pmid=23178150|pmc=3740377}}
12. ^{{cite journal|last1=Scavelli|first1=C|last2=Vacca|first2=A|last3=Di Pietro|first3=G|last4=Dammacco|first4=F|last5=Ribatti|first5=D|title=Crosstalk between angiogenesis and lymphangiogenesis in tumor progression|journal=Leukemia|date=1 April 2004|volume=18|issue=6|pages=1054–1058|doi=10.1038/sj.leu.2403355|pmid=15057248}}
13. ^{{cite journal|last1=Biswas|first1=S. K.|title=A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF- B and enhanced IRF-3/STAT1 activation)|journal=Blood|date=1 March 2006|volume=107|issue=5|pages=2112–2122|doi=10.1182/blood-2005-01-0428|pmid=16269622}}
14. ^{{cite journal|last1=Ojalvo|first1=Laureen S.|last2=King|first2=William|last3=Cox|first3=Dianne|last4=Pollard|first4=Jeffrey W.|title=High-Density Gene Expression Analysis of Tumor-Associated Macrophages from Mouse Mammary Tumors|journal=The American Journal of Pathology|date=March 2009|volume=174|issue=3|pages=1048–1064|doi=10.2353/ajpath.2009.080676|pmid=19218341|pmc=2665764}}
15. ^{{cite journal|last1=Kuang|first1=Dong-Ming|last2=Zhao|first2=Qiyi|last3=Peng|first3=Chen|last4=Xu|first4=Jing|last5=Zhang|first5=Jing-Ping|last6=Wu|first6=Changyou|last7=Zheng|first7=Limin|title=Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1|journal=The Journal of Experimental Medicine|date=8 June 2009|volume=206|issue=6|pages=1327–1337|doi=10.1084/jem.20082173|pmid=19451266|pmc=2715058}}
16. ^{{cite journal|last1=Kryczek|first1=Ilona|last2=Zou|first2=Linhua|last3=Rodriguez|first3=Paulo|last4=Zhu|first4=Gefeng|last5=Wei|first5=Shuang|last6=Mottram|first6=Peter|last7=Brumlik|first7=Michael|last8=Cheng|first8=Pui|last9=Curiel|first9=Tyler|last10=Myers|first10=Leann|last11=Lackner|first11=Andrew|last12=Alvarez|first12=Xavier|last13=Ochoa|first13=Augusto|last14=Chen|first14=Lieping|last15=Zou|first15=Weiping|title=B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma|journal=The Journal of Experimental Medicine|date=17 April 2006|volume=203|issue=4|pages=871–881|doi=10.1084/jem.20050930|pmid=16606666|pmc=2118300}}
17. ^{{cite journal|last1=Noy|first1=Roy|last2=Pollard|first2=Jeffrey W.|title=Tumor-Associated Macrophages: From Mechanisms to Therapy|journal=Immunity|date=July 2014|volume=41|issue=1|pages=49–61|doi=10.1016/j.immuni.2014.06.010|pmid=25035953|pmc=4137410}}
18. ^{{cite journal|last1=Doedens|first1=A. L.|last2=Stockmann|first2=C.|last3=Rubinstein|first3=M. P.|last4=Liao|first4=D.|last5=Zhang|first5=N.|last6=DeNardo|first6=D. G.|last7=Coussens|first7=L. M.|last8=Karin|first8=M.|last9=Goldrath|first9=A. W.|last10=Johnson|first10=R. S.|title=Macrophage Expression of Hypoxia-Inducible Factor-1 Suppresses T-Cell Function and Promotes Tumor Progression|journal=Cancer Research|date=14 September 2010|volume=70|issue=19|pages=7465–7475|doi=10.1158/0008-5472.CAN-10-1439|pmid=20841473|pmc=2948598}}
19. ^{{Cite journal|last=Chen|first=Lieping|last2=Rimm|first2=David L.|last3=Langermann|first3=Solomon|last4=Sanmamed|first4=Miguel F.|last5=Boto|first5=Agedi N.|last6=Herbst|first6=Roy S.|last7=O’Neill|first7=Thomas|last8=Archer|first8=Kristina A.|last9=Han|first9=Xue|date=2019-03-04|title=Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy|url=https://www.nature.com/articles/s41591-019-0374-x|journal=Nature Medicine|language=en|pages=1|doi=10.1038/s41591-019-0374-x|issn=1546-170X}}
20. ^1 {{cite journal|last1=Martinez|first1=Fernando O.|last2=Gordon|first2=Siamon|title=The M1 and M2 paradigm of macrophage activation: time for reassessment|journal=F1000Prime Reports|date=3 March 2014|volume=6|pages=13|doi=10.12703/P6-13|pmid=24669294|pmc=3944738}}
21. ^{{Cite journal | last1 = Allavena | first1 = P. | last2 = Sica | first2 = A. | last3 = Solinas | first3 = G. | last4 = Porta | first4 = C. | last5 = Mantovani | first5 = A. | title = The inflammatory micro-environment in tumor progression: The role of tumor-associated macrophages | doi = 10.1016/j.critrevonc.2007.07.004 | journal = Critical Reviews in Oncology/Hematology | volume = 66 | issue = 1 | pages = 1–9 | year = 2008 | pmid = 17913510| pmc = }}
22. ^De la Cruz-Merino L, Barco-Sanchez A, Henao Carrasco F, et al.: New insights into the role of the immune microenvironment in breast carcinoma. Dev Immunol 2013; 2013: 785317.
23. ^{{Cite journal|last=Williams|first=Carly Bess|last2=Yeh|first2=Elizabeth S|last3=Soloff|first3=Adam C|date=2016-01-20|title=Tumor-associated macrophages: unwitting accomplices in breast cancer malignancy|journal=Npj Breast Cancer|language=en|volume=2|issue=1|doi=10.1038/npjbcancer.2015.25|pmid=26998515|pmc=4794275|issn=2374-4677}}
24. ^{{cite journal|last1=Pyonteck|first1=Stephanie M.|last2=Akkari|first2=Leila|last3=Schuhmacher|first3=Alberto J.|last4=Bowman|first4=Robert L.|last5=Sevenich|first5=Lisa|last6=Quail|first6=Daniela F.|last7=Olson|first7=Oakley C.|last8=Quick|first8=Marsha L.|last9=Huse|first9=Jason T.|last10=Teijeiro|first10=Virginia|last11=Setty|first11=Manu|last12=Leslie|first12=Christina S.|last13=Oei|first13=Yoko|last14=Pedraza|first14=Alicia|last15=Zhang|first15=Jianan|last16=Brennan|first16=Cameron W.|last17=Sutton|first17=James C.|last18=Holland|first18=Eric C.|last19=Daniel|first19=Dylan|last20=Joyce|first20=Johanna A.|title=CSF-1R inhibition alters macrophage polarization and blocks glioma progression|journal=Nature Medicine|date=October 2013|volume=19|issue=10|pages=1264–1272|doi=10.1038/nm.3337|pmid=24056773|pmc=3840724|issn=1078-8956}}
25. ^{{cite journal |title=Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy |author=Cannarile|display-authors=etal |year=2017 |journal=Journal for ImmunoTherapy of Cancer |volume = 5|issue=1 |pages=53 |doi=10.1186/s40425-017-0257-y |pmid=28716061 |pmc=5514481 }}
26. ^{{Cite journal | doi=10.1200/JCO.2017.35.15_suppl.11078|title = A phase I/II dose escalation and expansion study of cabiralizumab (cabira; FPA-008), an anti-CSF1R antibody, in tenosynovial giant cell tumor (TGCT, diffuse pigmented villonodular synovitis D-PVNS)| journal=Journal of Clinical Oncology| volume=35| issue=15_suppl| pages=11078|year = 2017|last1 = Sankhala|first1 = Kamalesh Kumar| last2=Blay| first2=Jean-Yves| last3=Ganjoo| first3=Kristen N.| last4=Italiano| first4=Antoine| last5=Hassan| first5=Andrew Bassim| last6=Kim| first6=Tae Min| last7=Ravi| first7=Vinod| last8=Cassier| first8=Philippe Alexandre| last9=Rutkowski| first9=Piotr| last10=Sankar| first10=Neil| last11=Qazi| first11=Ibrahim| last12=Sikorski| first12=Robert S.| last13=Collins| first13=Helen| last14=Zhang| first14=Charlie| last15=Shocron| first15=Ellyn| last16=Gelderblom| first16=Hans}}
27. ^[https://clinicaltrials.gov/ct2/show/NCT03158272 A Study to of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread]
28. ^Novel Combination Shows Promising Responses in Pancreatic Cancer Nov 2017
29. ^{{Cite journal|last=Cuccarese|first=Michael F.|last2=Dubach|first2=J. Matthew|last3=Pfirschke|first3=Christina|last4=Engblom|first4=Camilla|last5=Garris|first5=Christopher|last6=Miller|first6=Miles A.|last7=Pittet|first7=Mikael J.|last8=Weissleder|first8=Ralph|date=2017-02-08|title=Heterogeneity of macrophage infiltration and therapeutic response in lung carcinoma revealed by 3D organ imaging|journal=Nature Communications|language=En|volume=8|pages=14293|doi=10.1038/ncomms14293|pmid=28176769|pmc=5309815|issn=2041-1723}}
30. ^1 {{Cite journal|last=Rodell|first=Christopher B.|last2=Arlauckas|first2=Sean P.|last3=Cuccarese|first3=Michael F.|last4=Garris|first4=Christopher S.|last5=Li|first5=Ran|last6=Ahmed|first6=Maaz S.|last7=Kohler|first7=Rainer H.|last8=Pittet|first8=Mikael J.|last9=Weissleder|first9=Ralph|date=2018-05-21|title=TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy|journal=Nature Biomedical Engineering|volume=2|issue=8|pages=578–588|language=En|doi=10.1038/s41551-018-0236-8|issn=2157-846X}}
31. ^1 {{cite journal|last1=Ruffell|first1=Brian|last2=Coussens|first2=Lisa M.|title=Macrophages and Therapeutic Resistance in Cancer|journal=Cancer Cell|date=April 2015|volume=27|issue=4|pages=462–472|doi=10.1016/j.ccell.2015.02.015|pmid=25858805|pmc=4400235}}
32. ^{{Cite journal|last=Guerriero|first=Jennifer L.|last2=Sotayo|first2=Alaba|last3=Ponichtera|first3=Holly E.|last4=Castrillon|first4=Jessica A.|last5=Pourzia|first5=Alexandra L.|last6=Schad|first6=Sara|last7=Johnson|first7=Shawn F.|last8=Carrasco|first8=Ruben D.|last9=Lazo|first9=Suzan|date=March 2017|title=Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages|journal=Nature|language=En|volume=543|issue=7645|pages=428–432|doi=10.1038/nature21409|pmid=28273064|issn=0028-0836}}

2 : Macrophages|Cancer
随便看

　

开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。

　

Copyright © 2023 OENC.NET All Rights Reserved
京ICP备2021023879号 更新时间：2024/11/14 0:07:34